

Alona Zer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/764504/publications.pdf>

Version: 2024-02-01

56
papers

2,866
citations

394421

19
h-index

254184

43
g-index

56
all docs

56
docs citations

56
times ranked

4344
citing authors

#	ARTICLE	IF	CITATIONS
1	ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data. <i>Oncologist</i> , 2022, 27, e76-e84.	3.7	3
2	Open-label phase 1/2 study evaluating the tolerability and antitumor activity of selinexor and pembrolizumab in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 110-110.	1.6	0
3	Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study. <i>Neuro-Oncology Advances</i> , 2022, 4, vdab188.	0.7	9
4	Quality of life (QoL) of OSE2101 in patients with HLA-A2+ non-small cell lung cancer (NSCLC) after failure to immune checkpoint inhibitors (IO): Final data of phase 3 Atalante-1 randomized trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9094-9094.	1.6	0
5	Personalized approach for response prediction and treatment management for non-small cell lung cancer patients based on a liquid biopsy.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21132-e21132.	1.6	0
6	Uncommon EGFR mutations on osimertinib, real-life data (UNICORN study): Updated results, brain efficacy, and resistance mechanisms.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9109-9109.	1.6	2
7	The trichoscopic features of hair shaft anomalies induced by epidermal growth factor receptor inhibitors: A case series. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 1178-1184.	1.2	3
8	Lower tumor volume is associated with increased benefit from immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, e125-e131.	1.1	3
9	Long term follow-up of EGFR mutated NSCLC cases. <i>Translational Oncology</i> , 2021, 14, 100934.	3.7	6
10	Alternative nivolumab duration and scheduling in advanced nonsmall cell lung cancer: A real-world evidence. <i>International Journal of Cancer</i> , 2021, 148, 1183-1191.	5.1	1
11	The Relationship of Diabetes Mellitus to Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer. <i>Oncology</i> , 2021, 99, 555-561.	1.9	13
12	Sarcoma incidence and subtype distribution in Israel – A population-based study. <i>Cancer Epidemiology</i> , 2021, 70, 101876.	1.9	2
13	Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung. , 2021, 9, e001999.		26
14	BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors. <i>Frontiers in Oncology</i> , 2021, 11, 603223.	2.8	9
15	Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1250-1258.	3.8	34
16	Open-label phase 1 study evaluating the tolerability and anti-tumor activity of selinexor and pembrolizumab in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e15579-e15579.	1.6	1
17	Integration of proteomic and clinical data for the prediction of response to immune checkpoint inhibitor therapy in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21110-e21110.	1.6	0
18	Clinicogenomic real-world data analysis of patients (pts) with KRAS G12C-mutant advanced non-small cell lung cancer (aNSCLC) from the natural history cohort of the Blood First Assay Screening Trial (BFAST).. <i>Journal of Clinical Oncology</i> , 2021, 39, 9023-9023.	1.6	0

#	ARTICLE	IF	CITATIONS
19	A phase 1b, open-label, single-arm study of cofetuzumab pelidotin (a PTK7-targeting antibody-drug) Tj ETQq1 1 0.784314 rgBT /Overl Clinical Oncology, 2021, 39, TPS3142-TPS3142.	1.6	1
20	Abdominal desmoid- course, unique genetic background, and severe outcomes in a large local series.. Journal of Clinical Oncology, 2021, 39, e23544-e23544.	1.6	0
21	Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer. JAMA Oncology, 2021, 7, 1133.	7.1	232
22	Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data. Oncoimmunology, 2021, 10, 1865653.	4.6	24
23	Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. Journal of Thoracic Oncology, 2020, 15, 618-627.	1.1	254
24	Can Ipilimumab restore immune response in advanced NSCLC after progression on anti-PD / PD-L1 agents?. Thoracic Cancer, 2020, 11, 2331-2334.	1.9	5
25	Treatment beyond progression with immune checkpoint inhibitors in non-small-cell lung cancer. Immunotherapy, 2020, 12, 235-243.	2.0	17
26	Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC). Lung Cancer, 2020, 143, 40-46.	2.0	38
27	Stereotactic body radiation therapy (SBRT) for the treatment of primary lung cancer in recipients of lung transplant. Radiology and Oncology, 2020, 54, 227-232.	1.7	2
28	BIOM-01. TYROSINE KINASE INHIBITORS AS A TREATMENT OF SYMPTOMATIC CNS METASTASES IN ONCOGENE-DRIVEN NSCLC. Neuro-Oncology, 2020, 22, ii1-ii1.	1.2	0
29	Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement, but Better Survival. Journal of Global Oncology, 2019, 5, 1-8.	0.5	21
30	Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2019, 20, 924-937.	10.7	1,133
31	Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life Cohort. Clinical Lung Cancer, 2019, 20, 278-286.e1.	2.6	10
32	Efficacy and Safety of <i>ALK</i>; Tyrosine Kinase Inhibitors in Elderly Patients with Advanced <i>ALK</i>-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort. Oncology Research and Treatment, 2019, 42, 275-282.	1.2	10
33	Primary cardiac sarcomas: A multi-national retrospective review. Cancer Medicine, 2019, 8, 104-110.	2.8	37
34	Hospitalisations and emergency department visits in cancer patients receiving systemic therapy: Systematic review and meta-analysis. European Journal of Cancer Care, 2019, 28, e12909.	1.5	33
35	A phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated Classic Kaposi sarcoma (CKS).. Journal of Clinical Oncology, 2019, 37, 11064-11064.	1.6	5
36	Multi-agent chemotherapy in advanced soft tissue sarcoma (STS) – A systematic review and meta-analysis. Cancer Treatment Reviews, 2018, 63, 71-78.	7.7	16

#	ARTICLE	IF	CITATIONS
37	Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data. <i>Lung Cancer</i> , 2018, 126, 217-223.	2.0	89
38	BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1128-1137.	1.1	160
39	High-Dose Radiotherapy as Neoadjuvant Treatment in Non-Small-Cell Lung Cancer. <i>Oncology</i> , 2018, 95, 13-19.	1.9	7
40	The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1705-1716.	1.1	38
41	Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, 426-434.e1.	2.6	102
42	Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi). <i>Lung Cancer</i> , 2018, 124, 117-124.	2.0	46
43	Neutrophils to lymphocytes ratio and platelets to lymphocytes ratio in pregnancy: A population study. <i>PLoS ONE</i> , 2018, 13, e0196706.	2.5	25
44	Association of Neurocognitive Deficits With Radiotherapy or Chemoradiotherapy for Patients With Head and Neck Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2018, 144, 71-79.	2.2	26
45	Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158. <i>Journal of Clinical Oncology</i> , 2018, 36, 8506-8506.	1.6	131
46	Rare targetable drivers (RTD) in NSCLC: PD-L1 expression, tumor mutation burden (TMB), microsatellite instability (MSI) and outcomes with immune check-point inhibitors (ICPi). <i>Journal of Clinical Oncology</i> , 2018, 36, 9076-9076.	1.6	0
47	ALK -Rearranged Non-Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism. <i>Clinical Lung Cancer</i> , 2017, 18, 156-161.	2.6	78
48	A Pharmacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	76
49	Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases. <i>Lung Cancer</i> , 2016, 98, 114-117.	2.0	127
50	Response to Yamamoto et al. <i>Journal of Thoracic Oncology</i> , 2016, 11, e129-e130.	1.1	0
51	Adjuvant Docetaxel and Cyclophosphamide (DC) with Prophylactic Granulocyte Colony-Stimulating Factor (G-CSF) on Days 8 & 12 in Breast Cancer Patients: A Retrospective Analysis. <i>PLoS ONE</i> , 2014, 9, e107273.	2.5	7
52	Landscape of genomic alterations (GA) detected by next-generation sequencing (NGS) in non-small cell lung cancer (NSCLC) adenocarcinoma in Israel. <i>Journal of Clinical Oncology</i> , 2014, 32, e19111-e19111.	1.6	0
53	Collaterals. <i>Journal of Thoracic Oncology</i> , 2013, 8, 662-663.	1.1	0
54	Tailoring Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer: A Historical Prospective Study. <i>Chemotherapy</i> , 2012, 58, 95-101.	1.6	2

#	ARTICLE	IF	CITATIONS
55	Adjuvant docetaxel and cyclophosphamide (DC) with prophylactic growth colony stimulating factor (GCSF) on days 8 and 12 in breast cancer patients: A retrospective analysis.. Journal of Clinical Oncology, 2012, 30, 202-202.	1.6	0
56	Cardiac Mass in a Rapidly Deteriorating Patient. Journal of Clinical Oncology, 2010, 28, e656-e658.	1.6	2